neo-gambogic acid has been researched along with Carcinoma, Non-Small Cell Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, C; Niu, H; Shen, D; Wang, Y | 1 |
| Fu, W; Lao, Y; Li, X; Meng, X; Qian, J; Tan, H; Tu, S; Xu, H; Xu, L; Xu, N; Zhang, L; Zhou, Q | 1 |
2 other study(ies) available for neo-gambogic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Gambogenic acid exerts anticancer effects in cisplatin‑resistant non‑small cell lung cancer cells.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; G1 Phase; Humans; Lung Neoplasms; Neoplasm Proteins; Xanthenes | 2020 |
Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Signal Transduction; Tumor Burden; Xanthenes; Xenograft Model Antitumor Assays | 2018 |